Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
497 Views
China Healthcare Weekly (Jun.1)-Akeso/Summit's Disappointing Ph3 Readout,Valuation Outlook of Biokin
​CR Sanjiu plans to transfer 49.8967% equity of Sanjiu (Anguo).Summit/Akeso's disappointing phase 3 readout raises doubts on FDA approval for...
514 Views
China Healthcare Weekly (Feb.16)-Update on CR Sanjiu's Acquisition of Tasly, the Impact of US Tariff
​China's biotech sells core assets too early, missing out on future benefits. US tariff impacts short-term, but will lead to industry upgrade. The...
817 Views
PegBio ć´ľć Ľç”źç‰© IPO: A (Supposedly) Straightforward GLP-1 Challenger Story
​PegBio plans to raise $100m in Hong Kong IPO, with focus on core product PB-117 as a GLP-1 challenger, but concerns arise upon closer examination...
470 Views
China Healthcare Weekly (Feb.2)- Update on CR Sanjiu's Acquisition of Tasly, China Biotech's Outlook
​Chinese biotech companies need to develop new blockbuster products to sustain growth.  A "supply side reform” benefits first-tier Biotech. The...
764 Views